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Background and aims: Liraglutide treatment can improve glycemic control with a concomitant weight loss, but
the underlying mechanism on weight loss is not completely understood. Cardiac natriuretic peptides (NPs) can
resist body fat accumulation through increasing adipocytes lypolysis. In this study, we tested the hypothesis that
liraglutide-induced weight loss was associated with increased plasma NPs concentrations.
Methods: Thirty-one outpatients with type 2 diabetes (T2D) treated with metformin and other oral antidiabetic
drugs except for thiazolidinediones (TZDs) were subcutaneously administered with liraglutide for 12 weeks. Body
composition, abdominal visceral adipose tissue areas (VAT) and subcutaneous adipose tissue areas (SAT) were
assessed at pre- and post-treatment by dual-energy X-ray absorptiometry (DXA) scanning and abdominal
computerized tomography (CT). Plasma atrial natriuretic peptides (ANP) and B-type ventricular natriuretic
peptides (BNP) concentrations were tested by commercial ELISA Kit quantitatively.
Results: Following 12-week liraglutide treatment, body weight, waist circumference, total fat and lean mass,
fat percentage, SAT and VAT areas were significantly reduced from baseline. Concurrently, plasma ANP and BNP
levels were significantly increased following 12-week liraglutide treatment. There were significant correlations
between the reductions in body compositions and the increases in both plasma ANP and BNP levels.
Conclusions: There were significant correlations between increases in both plasma ANP and BNP levels and
changes in liraglutide-induced body composition. Our data implied that increases in plasma NPs may add a novel
dimension to explain how liraglutide induces weight loss.
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The prevalence of obesity and diabetes has rapidly in-
creased worldwide including Western and Asian coun-
tries, it is estimated that 80% of type 2 diabetic patients
are obese [1]. In China, the combined prevalence of
overweight and obesity has increased nearly 50% in a
10-y period [2]. In this sense, it is necessary to develop* Correspondence: yudemintij@126.com
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stated.effective and efficient therapeutic strategy target for type 2
diabetes and obesity. Liraglutide, glucagon-like peptide-1
(GLP-1) analogue, is a member of the newest class of
T2D therapies currently available, which improve hyper-
glycemia through increasing insulin secretion and re-
ducing glucagon secretion [3], slowing gastric emptying,
delaying carbohydrate absorption, and increasing satiety,
leading to reduced caloric intake [4]. The Liraglutide
Effect and Action in Diabetes (LEAD)-2 and LEAD-3
studies have demonstrated that liraglutide treatment pro-
duced sustained improvements in glycaemic control with
a concomitant sustained weight loss and very low risk ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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shown that reductions in body weight with liraglutide pri-
marily come from reductions in fat mass rather than lean
tissue mass, furthermore, abdominal visceral fat tissues
(VAT) reduced greater than subcutaneous fat tissues
(SAT) [7]. Therefore liraglutide might be a promising new
agent for the treatment of T2D and abdominal obesity
linked to high risk of cardiovascular disease (CVD). In a
pilot study, we recently reported that liraglutide treatment
led to a mean reduction in body weight of 5.62 kg in
Chinese obese T2D [8], much greater than reported in
LEAD-2 and LEAD-3 studies [5,6], but the effect of
liraglutide-induced weight loss on body composition has
not been observed in Chinese T2D. In addition, the under-
lying mechanism on liraglutide-induced weight loss is not
completely understood.
The mechanisms underlying the weight-loss observed
with liraglutide are likely to be similar to those of native
GLP-1, potentially by slowing of gastric emptying [9], in-
creasing perception of satiety [10] and nausea [11], and/
or changing the secretion of other gastrointestinal hor-
mones [3]. A mean weight loss of up to 7.8 kg has also
been demonstrated in non-diabetic obese subjects
treated with liraglutide for 20 weeks and was apparently
not only due to induction of nausea and less energy in-
take [12]. In vitro study, GLP-1 was certified to increase
lipolysis in adipocytes in a dose-dependent manner [13].
In clinical study, Shalev and colleagues observed an
increase in resting energy expenditure of 27% with
peripheral GLP-1 administration in healthy men [14].
Recently, Minsuk Kim et al. demonstrated that cardiac
GLP-1R activation promotes the secretion of atrial natri-
uretic peptide (ANP) [15]. The cardiac natriuretic peptides
(NPs), ANP and BNP, are well known for key hormones in
fluid and hemodynamic homeostasis. Increases in circulat-
ing NPs were also shown to be associated with increased
postprandial fat oxidation, adipocytes lipolysis and result-
ant weight loss in both healthy and obese humans [16-18].
Furthermore, cross-sectional studies shown that obese in-
dividuals have lower natriuretic peptide concentrations
than individuals of normal weight [19,20], and patients
with metabolic syndrome often show reduced circulating
concentration and biological efficacy of NPs [21], indicat-
ing that obese individuals have relatively natriuretic defi-
ciency. Taken together, such studies led to an attractive
hypothesis that low plasma NPs levels might be associated
with obesity,and the capacity of promoting lipolysis makes
it an attractive target for anti-obesity therapies [22].
The increase in glucagon-like peptide-1 (GLP-1) activity
has emerged as a useful therapeutic tool of achieving and
maintaining good gylcemic control with concomitant
weight loss in T2D with obesity [5,6,8]. In this study, we
investigated whether liraglutide-induced weight loss was




This was a prospective, 12-week observational study of
subjects with T2D and obesity who were administrated
subcutaneous liraglutide as add-on therapy. Patients
were recruited from three diabetes specialists in the out-
patient setting of the Metabolic Disease Hospital of
Tianjin Medical University between September 2012 and
June 2013. The inclusion criteria were: 1) known T2D
with; 2) obesity (BMI ≥ 28 kg/m2); 3) HbA1c 7.0 ~ 10%,
and 4) at least 3 months treatment on a stable dose re-
gime of maximal dose of metformin, or combined with
either insulin, or any other oral anti-diabetes drugs ex-
cept for TZDs. The key exclusion criteria were: 1) a his-
tory of coronary artery disease based upon a history of
myocardial infarction, stable angina, congestive heart fail-
ure or unstable angina documented in physician notes or
cardiac catheterization, 2) significant renal impairment
(estimated creatinine clearance <60 ml/min or serum cre-
atinine >150 μmol/l) or liver damage (serum alanine or as-
partate aminotransferase three of more times the upper-
normal range); 3) treatment within the last 3 months with
pioglitazone, orlistat, any other drugs known to affect
weight control, including glucocorticoids, or tamoxifen.
During the 12-week study period, 31 of 35 eligible sub-
jects continued their usual diet and exercise regimens as
well as any concomitant glucose-lowering medications. All
patients were treated with the maximal metformin, 6 with
alpha-glucosidase inhibitor, 9 with glinide, 10 with glime-
piride and 6 with dipeptidyl peptidase-IV (DPP-IV) inhibi-
tor. Addition liraglutide was initiated at 0.6 mg once daily,
titrated to 1.2 mg once daily after one week. Insulin doses
or oral anti-diabetes drugs were reduced 0 ~ 50% upon
initiation of liraglutide based upon the prescribing dia-
betes specialists’ judgement. They could first decide to
discontinue oral insulin secretagogues in the events of
hypoglycemia or hypoglycemic symptoms occurred in the
daytime; if hypoglycemia occurred in the nighttime, the
investigators could consider decreasing insulin dose or
discontinuing insulin treatment according to their clinical
judgments. All subjects remained under the supervision of
the diabetes specialist team throughout the study. The
study protocol was approved by the Tianjin Medical Uni-
versity Ethics Committee Review Board and was con-
ducted in accordance with the Declaration of Helsinki and
Good Clinical Practice guidelines. All participants gave
their written informed consent before beginning the study.
Clinical examination
All of the blood draws were obtained in the fasted state
before and after 12-week liraglutide treatment. For the
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and post-treatment samples from the same patient were
paired. The blood samples were taken and immediately
cooled and centrifuged at 4°C, then stored at -80°C until
analysis.
HbA1c was analyzed using a high-performance liquid
chromatography, ion-exchange chromatography assay
(HLC-723G7, TOSOH, Japan). Serum concentrations of
insulin and C-peptide were analyzed by enzyme linked
immuno sorbent assay (ELISA) methods. Serum glucose,
lipid profiles and liver biochemistry were determined by
using the Hitachi 7070 automatic biochemical analyzer
(Hitachi Ltd, Japan). Plasma ANP and BNP levels were
quantified by commercial ELISA Kit (Biovendor, Mordrice,
Czech Republic) performed according to the manufac-
turer’s instructions. Each sample was run in triplicates
and the mean value was obtained by calculation using
the standard curve method. Paired pre- and post-
treatment samples were run on the same ELISA plate
to minimize plate-related assay variation. The detection
limits of the ELISA were 2.3 pg/ml for ANP plasma
levels and 1.02 pg/ml for BNP levels with an intra-assay
coefficient of variation (CV) of (7.8% ~ 9.9%) and inter-
assay CV of (8.1% ~ 15%) for both ANP and BNP.
Body composition
Body weight was measured at all visits without shoes
and wearing only light clothing by Tanita scales analyzer
(Tanita TCS-WB-3000, UK). Height was measured using
a stadiometer to the nearest 0.5 cm. Waist circumfer-
ence was taken at the midpoint between the anterior su-
perior iliac spine and the lower edge of the rib cage. A
single observer, who was not involved in the clinical care
of the patients, made all of the above measurements.
Lean tissue mass, fat mass, and total body weight were
assessed before treatment by a low radiation DXA (GE
Prodigy, WI USA) scan in all fasting subjects and again
after the 12-week liraglutide intervention period. Ab-
dominal visceral and subcutaneous adipose tissue areas
measured by single-slice abdominal CT have been
shown to have a strong direct linear correlation with vis-
ceral and abdominal subcutaneous tissue mass respect-
ively [23], allowing for changes in these two tissue types
to be compared. At baseline and after treatment, sub-
jects were placed in the supine position and a truncal
CT scan was performed using GE Discovery CT 750 HD
scanner (GE Healthcare, Milwaukee, WI, USA) with slice
thickness set at 5 mm. The images were analyzed using
image analysis software (ImageJ, version 1.43q; National
Institutes of Health, Bethesda, MD, USA) with an at-
tenuation range of −50 to −250 Hounsfield units to
quantify the subcutaneous, visceral, and total abdominal
adipose tissue areas at the level of the intervertebral disc
between lumbar vertebrae four and five (L4:L5). Theresults were expressed in centimeter square. The vis-
ceral/subcutaneous adipose tissue area ratio (VAT/SAT
ratio) was calculated. All DXA and CT scans were per-
formed by a single specialist using the same equipment
and assessed by a single reader who was blinded to the
study question, patient and follow-up time point.
Statistical analysis
Normally distributed data are expressed as mean ±
standard deviation and non-normally distributed data as
median or as numbers and percentages. Non-normally
distributed data were log transformed for use with para-
metric statistics. Paired t-tests were used to assess the
differences in body composition, cardiac NPs levels and
laboratory parameters between individuals at pre- and
post-treatment (pre - post) and are presented as mean dif-
ferences with 95% confidence intervals. Unpaired t-tests
were used to compare the changes between different body
composition intra-individuals after treatment and the
difference between subgroups. Pearson correlation ana-
lysis was used to assess possible relationships between
alterations of plasma cardiac NP levels and body com-
position and other laboratory data. The statistical ana-
lyses were performed using SPSS windows version 17.0,




31 of the 35 eligible subjects who were underwent baseline
scanning completed the study. The 4 dropouts initiated
treatment after baseline assessments, one declined follow-
up, one changed hospital and two discontinued GLP-1
treatment due to gastrointestinal side effects. Table 1
shows baseline characteristics of 31 subjects (16 male, 15
female) at admission. The mean age was 48.5 ± 11.4 years,
the mean glycated hemoglobin (HbA1c) was 8.2 ± 0.77%,
and mean body mass index (BMI) was 31.7 ± 3.6 kg/m2.
All patients were treated with the maximal tolerated dose
of metformin before recruitment and they remained on
the same mean dose throughout the study. The oral anti-
diabetes agent histories of subjects were seen in Table 1.
These parameters indicated that the enrolled subjects had
severe abdominal obesity and poor glycemic control.
Changes in body composition following 12-week
liraglutide treatment
Body weight, waist circumference and BMI were signifi-
cantly decreased from baseline to post-treatment with
liraglutide in all subjects, the mean reductions in body
weight, waist circumference and BMI were 5.03 kg,
3.00 cm and 1.74 kg/m2 respectively (Table 2). 61.3%
(n = 19) of the subjects in the study lost more than 5%
of body weight from baseline. There was no correlation
Table 2 Changes in body composition and metabolic parame
Variable Pre-treatment (n = 31) Post-treatm
Weight (kg) 91.6 ± 12.4 86.5 ± 12.5
BMI (kg/m2) 31.7 ± 3.6 29.9 ± 3.8
waist circumference (cm) 108.7 ± 8.8 105.7 ± 9.2
Total fat mass (kg) 33.77 ± 10.33 29.98 ±10.76
Total lean mass (kg) 54.88 ± 8.42 53.36 ± 8.34
Relative total body Fat (%) 37.89 ± 8.22 35.60 ± 9.01
Relative total body Lean (%) 62.06 ± 8.22 64.39 ± 9.01
Abdominal VAT areas (cm2) 277.80 ± 68.75 235.49 ± 65.6
Abdominal SAT areas (cm2) 212.65 ± 83.17 189.35 ± 83.3
VAT:SAT ratio 1.41 ± 0.62 1.34 ± 0.64
HbA1c (%) 8.19 ± 0.77 7.13 ± 0.54
FBG (mmol/L) 8.63 ± 1.20 6.86 ± 0.73
P2BG (mmol/L) 13.05 ± 2.72 8.66 ± 0.91
sFCP (ng/mL) 2.23 ±1.17 3.51 ±1.80
CPI 1.47 ±1.01 2.74 ±1.47
HOMA-IR 9.15 ± 4.63 6.55 ± 2.93
SBP (mmHg) 138.2 ± 11.2 132.9 ± 12.3
DBP (mmHg) 85.9 ± 6.4 83.4 ± 8.0
TG (mmol/L) 2.89 ± 1.74 1.67 ± 0.60
TC (mmol/L) 5.14 ± 1.17 4.40 ± 0.97
LDL-C (mmol/L) 2.90 ± 0.87 2.79 ± 0.78
HDL-C (mmol/L) 1.26 ± 0.23 1.36 ± 0.22
Normally distributed data expressed as mean ± standard deviation and non-normal
Non-normally distributed data were log-transformed for use with parametric statist
body weight. Relative total body Lean: lean percentage of total body weight. SAT: s
haemoglobin A1c. FBG: fasting blood glucose. P2BG: 2-hour postprandial blood gluc
model assessment of insulin resistance. CPI = sFCP (ng/mL) × 100/fasting glucose (m
lower 95% confidence interval limit, upper 95% confidence interval limit. SBP: systo
cholesterol. LDL-C: low density lipoprotein-cholesterol. HDL-C: high density lipoprot
Table 1 Baseline characteristics
Variable Baseline (n = 31)
Sex (Male/Female) 16/15
Age (years) 48.5 ± 11.4
Duration of diabetes (years) 6.9 ± 4.1
HbA1c (%) 8.2 ± 0.77
Body weight (kg) 91.6 ± 12.4
BMI (kg/m2) 31.7 ± 3.6
Waist circumference (cm) 108.7 ± 8.8
Medications for Diabetes
Metformin (n, %) 31 (100%)
Sulphonylurea (n, %) 10 (32.3%)
Alpha-glucosidase inhibitor (n, %) 6 (19.4%)
Glinide (n, %) 9 (29.0%)
DPP-IV inhibitor (n, %) 6 (19.4%)
Normally distributed data expressed as mean ± standard deviation and
non-normally distributed data expressed as median or as numbers and
percentages. HbA1c: glycosylated haemoglobin A1c. BMI: body mass index.
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tion in body weight (r = -0.27, p = 0.886).
DXA assessments
Absolute and relative changes in total body fat mass and
lean tissue mass
There were significant absolute reductions in both total
body fat and lean mass from baseline to post-treatment
with liraglutide in the subjects (Table 2). Furthermore,
the mean absolute reduction in total fat mass of 3.79 kg
was significantly greater than the lean mass of 1.52 kg in
the intra-individuals (Table 2). And the relative mean fat
mass reduction (percentage of pre-treatment total fat
mass) of 12.3% was also greater than the relative lean
mass reduction of 2.8% (Table 2). The relative total body
fat mass (percentage of total body weight) was reduced
by 2.3% from baseline of 37.9% to 35.6%, while the rela-
tive total body lean mass was increased by 2.3% from
baseline of 62.1% to 64.4%, the changes were signifi-
cantly different (Table 2). There was no correlationters following 12-week liraglutide treatment
ent (n = 31) Mean changes from baseline (95% CI) p value
-5.03 (-5.81, -3.80) <0.001
-1.74 (-2.02, -1.31) <0.001
-3.00 (-3.89, -2.11) <0.001
-3.79 (-4.53, -3.05) <0.001
-1.52 (-2.03, -1.10) <0.001
-2.29 (-2.91, -1.66) <0.001
2.34 (1.67, 3.01) <0.001
2 -42.31 (-50.28, -34.33) <0.001
7 -23.29 (-29.43, -17.16) <0.001
-0.06 (-0.11, -0.02) 0.009
-1.06 (-1.25, -0.87) <0.001
-1.77 (-2.16, -1.39) <0.001
-4.39 (-5.24, -3.54) <0.001
1.27 (0.73, 1.81) 0.001
1.27 (0.58, 1.97) <0.001
-2.60 (-3.96, -1.25) 0.001
-5.3 (-7.9, -2.6) <0.001
-2.5 (-4.2, -0.8) 0.005
-1.22 (-1.87, -0.57) 0.001
-0.75 (-1.27, -0.23) 0.007
-0.11 (-0.45, -0.23) 0.511
0.10 (0.03, 0.16) 0.006
ly distributed data expressed as median or as numbers and percentages.
ics. BMI: body mass index. Relative total body Fat: fat percentage of total
ubcutaneous adipose tissue. VAT: visceral adipose tissue. HbA1c: glycosylated
ose. sFCP: serum fasting C-peptide. CPI: C-peptide index. HOMA-IR: homeostasis
g/dL). HOMA-IR = fasting glucose (mg/dL) × fasting insulin (μU/ml)/405. 95% CI:
lic blood pressure. DBP: diastolic blood pressure. TG: triglyceride. TC: total
ein-cholesterol.
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total body fat tissue (r = -0.052, p = 0.781) and lean tissue
(r = 0.02, p = 0.916).
CT Assessments
Visceral and abdominal subcutaneous tissue areas
There were significant reductions in both abdominal
VAT and SAT areas from baseline to post-treatment with
liraglutide in the subjects (Table 2). The mean absolute
reduction in abdominal VAT areas of 42.3 cm2 was sig-
nificantly greater than the SAT areas of 23.3 cm2 in the
intra-individuals (t = -3.861, p<0.001). And the relative
mean reduction in VAT areas (percentage of total ab-
dominal fat mass areas) of 15.2% was also greater than
the relative SAT areas reduction of 10.3% (t = -2.605,
p = 0.012). In addition, there was a significant change in
VAT/SAT ratio before and after treatment (1.41 to 1.34,
Table 2). There was no correlation between pre-
treatment body weight and the reduction in abdominal
VAT areas (r = 0.18, p = 0.333) and SAT areas (r = -0.353,
p = 0.052). These data indicated that liraglutide led to
weight loss as a result of a reduction in fat tissue, espe-
cially in visceral fat tissue.
Changes in parameters relating to glucose metabolism
following 12-week liraglutide treatment
As expected, 12-week treatment with liraglutide was as-
sociated with significant mean reductions in HbA1c of
1.06%, FBG of 1.77 mmol/L and P2BG of 4.39 mmol/L,
respectively (Table 2), but it was not seen a significant
direct linear correlation between changes in body fat
reduction and HbA1c decreased (r = 0.093, p = 0.619).
Serum fasting C-peptide and C-peptide index (CPI) were
significantly increased in all subjects by liraglutide treat-
ment. Liraglutide also significantly improved insulin re-
sistance indexed by HOMA-IR (Table 2). Furthermore,
there was a weak but significant correlation between
change in body fat and change in HOMA-IR (r = 0.35,
p = 0.042). These data indicated that liraglutide treatment
could ameliorate insulin secretion and insulin resistance.
Changes in lipid profiles and blood pressure
By the end of the 12-week treatment period, the TG
and TC levels were significantly decreased, while the
HDL-C level was increased. The mean changes in TG was
-1.22 mmol/L (t = -3.926, p = 0.001), TC was -0.75 mmol/L
(t = -2.983, p = 0.007) and HDL-C was 0.10 mmol/L
(t = 3.075, p = 0.006). However, there was no significant
change in the concentration of LDL-C (t = -0.668,
p = 0.511). Further more, significant reductions in both
the SBP and DBP were observed in present study, the
mean changes were -5.3 mmHg (t = -4.008, p<0.001)
and -2.5 mmHg (t = -3.053, p = 0.005), respectively (Table 2).Changes in plasma cardiac natriuretic peptides levels
Both the plasma ANP and BNP levels were significantly
increased following the 12-week liraglutide treatment
(ANP from baseline 11.16 ± 3.89 ng/mL to 16.91 ±
4.64 ng/mL; BNP from baseline 25.64 ± 6.72 ng/mL to
33.29 ± 7.48 ng/mL, respectively, Figure 1A, 1B) in all
the subjects. Reinforcing this, when we stratified
patients into subgroups according to amount of weight
loss < 5% or ≥ 5% [patients with < 5% weight loss (n = 12)
and patients with ≥ 5% weight loss (n = 19), the character-
istics of the subgroups were seen in Additional file 1:
Table S1], there was a significant increase in ANP levels in
patients who lost weigh more than 5% compared with
those who lost weight less than 5% (7.50 ± 1.59 ng/mL
vs. 2.96 ± 0.88 ng/mL, p<0.001, Figure 1C). Similar to
ANP levels, the mean increment of BNP levels in the pa-
tients who lost weight more than 5% was significant
greater than those who lost weight less than 5% (10.09 ±
2.57 ng/mL vs. 2.61 ± 0.75 ng/mL, p<0.001, Figure 1D).
Relationships between changes in body compositions
and pre-treatment cardiac NPs levels following 12-week
liraglutide treatment
Results are presented in Additional file 2: Table S2.
Unexpectedly, there was no correlations between pretreat-
ment ANP levels and changes in body compositions fol-
lowing 12-week liraglutide treatment (p = 0.096-0.961).
However, BNP levels at pre-treatment were weak but
significant related to changes in body weight (r = 0.497,
p = 0.004), fat mass (r = 0.487, p = 0.005), relative fat
mass (r = 0.497, p = 0.004), lean mass (r = 0.514, p = 0.003)
and VAT areas (r = 0.385, p = 0.032), but not related to
changes in SAT areas (r = 0.306, p = 0.095).
Relationships between changes in body compositions and
changes in cardiac NPs levels following 12-week liraglutide
treatment
Results are presented in Additional file 2: Table S2. As hy-
pothesized, there was significant inverse correlations be-
tween increases in ANP levels and changes in body weight
(r = -0.748, p<0.001, Figure 2A), fat tissue (r = -0.61,
p<0.001, Figure 2B), relative fat (r = -0.572, p = 0.001,
Figure 2C), lean tissue (r = -0.601, p<0.001, Figure 2D),
VAT (r = -0.595, p<0.001, Figure 2E), and SAT (r = -0.426,
p = 0.017, Figure 2F). And the significant inverse correlation
was also seen in the increase in BNP levels and reductions in
total body fat tissue (r = -0.61, p<0.001), relative fat (r = 0.616,
p<0.001), lean tissue (r = -0.612, p<0.001), VAT (r = -0.669,
p<0.001) and SAT (r = -0.474, p = 0.007) (Figure 3).
Discussion
In addition to the expected achieving good glycemic
control, this study demonstrated that treatment with lir-
aglutide over a 12-week period led to a mean weight loss
Figure 1 Changes in the plasma ANP and BNP levels following 12-week liraglutide treatment. ANP: A-type natriuretic peptides. BNP: B-type
ventricular natriuretic peptides. (A) and (B): Changes in the plasma ANP and BNP levels at pre-treatment and post-treatment respectively. (C) and
(D): Comparisons the increases in the ANP and BNP levels within two subgroups stratified by reductions of body weight loss: subjects who lost
weight more than 5% and subjects who lost weight less than 5%.
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weight did not change, and 61.3% of the subjects lost
more than 5% of body weight from baseline. We also ob-
served the changes of liraglutide-induced body compos-
ition assessed by DXA and CT. It was shown that
reductions in body weight with liraglutide primarily
came from reductions in fat mass rather than lean mass,
and decreases in VAT area seemed greater than in SAT.
The most interesting findings reported here were the
significant correlations between weight loss and in-
creases in both plasma ANP and BNP levels following
12-week liraglutide treatment. We also found that NPs
increased particularly more in patients who lost weight
more than 5% compared with patients who lost weight
less than 5%, suggesting the possible role of increases in
circulation NPs levels on the liraglutide-induced weight
loss. Given the “rediscovery” of brown adipocytes in
adult humans [24,25] and the potential role of ANP and
BNP to stimulate the appearance of brown-like adipo-
cytes associated with increased expenditure, our results
imply that increases in plasma NPs may add another di-
mension to explain how liraglutide induces sustained
weight loss.Liraglutide-induced weight loss might be associated with
increases in plasma NPs concentrations
The LEAD-2 [5] and LEAD-3 [6] studies have shown
that liraglutide (as monotherapy or in combination with
metformin) resulted in greater reductions in fat mass
(1.0–2.4 kg) than in lean mass (1.5 kg), confirming our
results in which fat mass decreased 3.8 kg and lean mass
decreased 1.5 kg after 12-week liraglutide treatment. In
addition, the results from CT assessment were also in
line with the results from LEAD-2 [5] shown reductions
in VAT area were larger than SAT. These are all desir-
able traits because increased fat mass are associated with
decreased insulin sensitivity and increased morbidity
and mortality, furthermore, visceral fat is causally associ-
ated with insulin resistance [26]. In this study, we found
that there was a significant correlation between change
in total body fat and change in HOMA-IR. Noticeable,
the reductions in fat mass in our study were greater than
those of previous studies in terms of the changes in
liraglutide-induced body composition, including the
LEAD-2 [5], LEAD-3 [6] studies, as well as a shorter
study in which fat mass decreased 1.0 kg after 8-week
treatment with liraglutide 0.6 mg once-daily [27]. What
Figure 2 Correlations between changes in ANP and body compositions following 12-week liraglutide treatment. Δ: The change of values
following liraglutide treatment. ANP: A-type natriuretic peptides. SAT: subcutaneous adipose tissue. VAT: visceral adipose tissue. (A): Change in
plasma ANP levels and change in body weight. (B): Change in plasma ANP levels and change in fat mass. (C): Change in plasma ANP levels and
change in relative fat mass. (D): Change in plasma ANP levels and change in lean mass. (E): Change in plasma ANP levels and change in VAT
areas. (F): Change in plasma ANP levels and change in SAT areas.
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study? It might be because body fat distribution differs
across ethnic background, Chinese and South Asian co-
horts had relatively greater amount of abdominal adi-
pose tissue, and this difference was more pronounced in
VAT [28]. It is possible that liraglutide exhibited its ut-
most effectiveness on weight reduction merely due to
genetic differences, confirming the hypothesis of one re-
cent study from Japanese in which liraglutide adminis-
trated 0.9 mg once-daily achieved about 10% of body
weight reduction after 6 months, the result was also
much greater than those mainly done in Caucasians
[13,29], however the Japanese study failed to observe the
reductions in body fat tissue, and the present study using
DXA and CT to assess the changes in liraglutide-induced
body compositions only performed in Chinese obese T2D.
Therefore, the excellent results of liraglutide-induced re-
ductions in fat tissue should be supported in the future in
a double-blind placebo-controlled clinical trial across eth-
nic groups.
Lowering of energy intake has been shown with lira-
glutide as well as native GLP-1 both in animals [30,31]
and human subjects [10]. In rats, intracerebroventricular
administration of GLP-1 has been shown to induce amarked reduction in food intake, presumably by interact-
ing with GLP-1 receptors, which are present in several
areas in the central nervous system [32,33]. In pharmaco-
logical doses, exogenous administration of GLP-1 has
been shown to slow gastric emptying substantially [9]. In
clinical studies, it was demonstrated that appetite, food
preference and eating behavior were significantly changed
by liraglutide treatment [34-36]. Therefore, the underlying
mechanisms of liraglutide inducing weight loss are partly
related to the combined effects of GLP-1 on the gastro-
intestinal tract and the brain, leading to delaying gastric
emptying, inducing satiety and changing eating behavior
to reduce the energy intake.
The effect of liraglutide on energy expenditure is a
novel observation that requires further investigation
[27,34]. In patients with T2D or not with liraglutide
treatment, a weight loss of 2.4 kg ~7.8 kg could be main-
tained over 52 weeks to 2 years. Since gastrointestinal ef-
fects such as vomiting and nauseas were mostly
transient, it was apparent that induction of nausea and
less energy intake cannot fully explain the liraglutide-
induced weight loss in such long term [30]. Recently, it
was reported that GLP-1 could increase adipocytes lip-
olysis in a dose-dependent manner [13]. Moreover,
Figure 3 Correlations between changes in BNP levels and body compositions following 12-week liraglutide treatment. Δ: The change of
values following liraglutide treatment. BNP: B-type natriuretic peptides. SAT: subcutaneous adipose tissue. VAT: visceral adipose tissue. (A): Change
in plasma BNP levels and change in body weight. (B): Change in plasma BNP levels and change in fat mass. (C): Change in plasma BNP levels
and change in relative fat mass. (D): Change in plasma BNP levels and change in lean mass. (E): Change in plasma BNP levels and change in VAT
areas. (F): Change in plasma BNP levels and change in SAT areas.
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1R activation promoted the secretion of atrial natriuretic
peptide (ANP) [15]. NPs were also shown to increase
lipid oxidation and adipocyte thermogenesis [18], which
was subsequently found to promote “browning” of
white adipocytes in mouse and human adipocytes
through p38 MAPK pathway [37]. In addition, increases
in plasma NPs levels were proved to be associated with
weight loss induced by gastric bypass surgery [38] and
lifestyle changes in human [39], suggesting that in-
creased NPs play an important role in the weight loss. An
attractive hypothesis was raised whether the liraglutide-
induced weight loss is associated with the increased cir-
culation NPs levels. In our study, we found that in-
creases in both ANP and BNP levels with liraglutide
treatment were associated with reductions in body
weight. Moreover, the patients who lost weight more
than 5% had approximate 2.5-fold and 3.9-fold intra-
individual increases in plasma ANP and BNP levels re-
spectively, compared with the patients who lost weight
less than 5% (Figure 2C and Figure 2D). Taken together,
our data suggested that liraglutide-induced weight loss
primarily from reductions in fat mass might be associ-
ated with changes in the NP system.Possible mechanisms of liraglutide increasing circulating
NPs levels
The mechanisms underlying the relative NPs deficiency
in obesity are not clear. NP clearance receptors (NPRC)
which was found on adipocytes, referred to as the clear-
ance receptor binds ANP and BNP to remove them from
circulation, and elevated NPRC have been demonstrated
in patients with obesity, suggesting that a putative role
for adipose tissue in the clearance of NPs from the cir-
culation [40-42]. This is supported by an animal model
of NPRC-/- null mice in which reduced adipose tissue as-
sociated with increased NPs has been observed, and the
typical brown adipocyte markers were elevated in both
BAT and WAT [37]. It is well known that NPs are syn-
thesized and released from the ventricles in response to
increased cardiac wall. In this study, we excluded the pa-
tients with heart failure at baseline that would account
for the observed increase in NPs levels. Moreover, the
protective role of GLP-1 in cardiovascular disease has
been suggested in both animal experiments and clinical
studies. Bao W et al. revealed that the long acting GLP-1
receptor agonist could provid more sustained cadioprotec-
tive effect in the setting of acute myocardial I/R injury
than the short-acting exendin-4 [43]. Clinically, beneficial
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with heart failure [44]. Endogenous GLP-1 level was found
to be increased in patients with high cardiovascular risk,
suggesting it represent a contra-regulatory response in
states of metabolic disorder, hepertriglyceridemia and in-
sulin resistance [45]. In accordance with those previous
studies, we observed that treatment with liraglutide could
significantly improve cardiovascular risk factors including
triglycride, total cholesterol, HDL cholesterol and blood
pressure, but not the LDL cholesterol. A study among the
Japanese obese patients with T2D also found a signifi-
cantly reduction in LDL-C with liraglutide at 6 months
after discharge [35]. In addition, a recent study demon-
strated that liraglutide led to a reduction of blood pressure
through activating the secretion of ANP, but this effect
was eliminated in the GLP-1R deficient mouse model,
suggesting that liraglutide regulate blood pressure via
GLP-1R and ANP axis dependent way [15]. We therefore
hypothesized that the increases in the NPs levels were not
secondary to underlying cardiac changes, but attributed to
the liraglutide treatment. With a deeper molecular and
clinical understanding of how liraglutide increase NPs
levels to regulate fat metabolism and cardiovascular func-
tion in the future, the researchers may find new ways to
manage obese T2D.Limitations and conclusion
Several limitations of the present study deserve mention.
The study involves a relative small sample size and an
observational design without use of control subjects.
The future study need to confirm our results, which
should be to power a larger, more definitive study in-
corporating appropriate controls. This might include a
patient group treated with an agent that improves gly-
cemic control but not induce weight loss and a second
group in whom weight loss alone is achieved (e.g. orli-
stat) to determine the independent effect on increases in
NPs levels following liraglutide treatment. Additionally,
the future study should be designed to observe the lon-
gitudinal changes of NPs following liraglutide-induced
weight loss.
In summary, we found there was a significant correl-
ation between the increases in NPs levels and the reduc-
tions in weight loss following the 12-week liraglutide
treatment. We also showed that NPs increased particu-
larly more so in patients who lost weight more than 5%
compared with patients who lost weight less than 5%.
Our data imply that increases in plasma NPs may add
another novel dimension to explain how liraglutide in-
duces sustained weight loss. It would seem that a much
better understanding of the molecular basis for changes
in NPs following the weight loss induced by liraglutide is
needed in the future.Additional files
Additional file 1: Table S1. Characteristics of subgroup subjects.
Additional file 2: Table S2. Correlations between changes in body
compositions and plasma NPs levels following 12-week liraglutide
treatment.
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